Latest data from the Hong Kong Stock Exchange reveals a significant share purchase by a key company insider.

On June 10th, Executive Director and Chief Executive Officer Yang Jianshu acquired an additional 145,000 shares of CStone Pharmaceuticals-B (HKEX: 02616).

The transaction was executed at an average price of approximately HK$4.2593 per share, amounting to a total investment of about HK$617,600.

Following this purchase, Dr. Yang's total shareholding has increased to roughly 72.4831 million shares, representing a 4.53% stake in the company.

Additional notes indicate that the shares were purchased in the open market using Dr. Yang's personal funds.

The acquired shares correspond to Restricted Share Units and Share Options granted or to be issued under the company's Pre-IPO RSU Scheme, Pre-IPO Share Option Scheme, and Post-IPO Incentive Schemes.